Contact
searchSearch
HMP Global
Login

Follicular Lymphoma Specialty Channel

Follicular Lymphoma
Specialty Channel
Quiz
CAR T-Cell Therapies and Survival Outcomes Among Patients With R/R FL
12/03/2025
True or False: According to results from a comparative analysis, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, demonstrated superior survival outcomes among patients with R/R...
True or False: According to results from a comparative analysis, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, demonstrated superior survival outcomes among patients with R/R...
True or False: According to...
12/03/2025
Oncology
News
Pathologic Grade and Peripheral Blood NK Cell Percentage May Predict Outcomes Among Patients With Follicular Lymphoma
12/03/2025
Emily Estrada
Pathological grade and natural killer cell levels may serve as clinically useful biomarkers for prognosis among patients with follicular lymphoma, according to a real-world study.
Pathological grade and natural killer cell levels may serve as clinically useful biomarkers for prognosis among patients with follicular lymphoma, according to a real-world study.
Pathological grade and natural...
12/03/2025
Oncology
News
Real-World Safety Analysis Identifies Undocumented Adverse Events Among Patients With Follicular Lymphoma Treated With Obinutuzumab
12/03/2025
Emily Estrada
A real-world pharmacovigilance analysis of reports from the FAERS and JADER databases identified previously undocumented adverse events linked to obinutuzumab therapy for patients wtih follicular lymphoma and chronic lymphocytic leukemia.
A real-world pharmacovigilance analysis of reports from the FAERS and JADER databases identified previously undocumented adverse events linked to obinutuzumab therapy for patients wtih follicular lymphoma and chronic lymphocytic leukemia.
A real-world pharmacovigilance...
12/03/2025
Oncology
FDA Approval
FDA Grants Approval to Epcoritamab for Patients With R/R Follicular Lymphoma
11/18/2025
Gina Tomaine
On November 18, 2025, the US Food and Drug Administration granted approval to epcoritamab-bysp with lenalidomide and rituximab for the treatment of patients with relapsed/refractory follicular lymphoma.
On November 18, 2025, the US Food and Drug Administration granted approval to epcoritamab-bysp with lenalidomide and rituximab for the treatment of patients with relapsed/refractory follicular lymphoma.
On November 18, 2025, the US...
11/18/2025
Oncology
News
CAR T-Cell Therapy Offers Superior Efficacy Over Bispecific Antibodies for R/R Follicular Lymphoma but With Higher Toxicity, Meta-Analysis Finds
11/05/2025
Emily Estrada
For patients with R/R FL, treatment with CAR T-cell therapy demonstrated superior responses compared to treatment with bispecific antibodies, despite an increased risk for neurotoxicity, according to a systematic review.
For patients with R/R FL, treatment with CAR T-cell therapy demonstrated superior responses compared to treatment with bispecific antibodies, despite an increased risk for neurotoxicity, according to a systematic review.
For patients with R/R FL,...
11/05/2025
Oncology
News
Fixed-Duration Epcoritamab Plus R2 Produces High Response Rates and Favorable Outcomes for R/R Follicular Lymphoma
11/05/2025
Emily Estrada
A regimen of fixed-duration epcoritamab with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma showed deep and durable responses, according to updated results from the EPCORE NHL-2 trial.
A regimen of fixed-duration epcoritamab with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma showed deep and durable responses, according to updated results from the EPCORE NHL-2 trial.
A regimen of fixed-duration...
11/05/2025
Oncology
News
CAR T-Cell Therapies Show Superior Survival Outcomes Compared to Real-World Salvage Treatments for R/R Follicular Lymphoma
11/05/2025
Emily Estrada
In a real-world setting, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel demonstrate superior survival outcomes compared to traditional salvage therapy for patients with follicular...
In a real-world setting, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel demonstrate superior survival outcomes compared to traditional salvage therapy for patients with follicular...
In a real-world setting, CAR...
11/05/2025
Oncology
Quiz
Relmacabtagene Autoleucel for R/R Follicular Lymphoma
10/30/2025
Emily Estrada
True or False: Among heavily pretreated patients with R/R follicular lymphoma, relmacabtagene autoleucel demonstrated deep and durable responses with a favorable safety profile, according to results from the phase 2 RELIANCE study.
True or False: Among heavily pretreated patients with R/R follicular lymphoma, relmacabtagene autoleucel demonstrated deep and durable responses with a favorable safety profile, according to results from the phase 2 RELIANCE study.
True or False: Among heavily...
10/30/2025
Oncology
News
Relmacabtagene Autoleucel Achieves Durable Responses With Manageable Safety For R/R FL: 2-Year Follow-Up From RELIANCE Study
09/29/2025
Emily Estrada
At a 2-year follow-up, relmacabtagene autoleucel demonstrates deep and durable responses for patients with relapsed/refractory follicular lymphoma who have had 3 or more prior lines of therapy.
At a 2-year follow-up, relmacabtagene autoleucel demonstrates deep and durable responses for patients with relapsed/refractory follicular lymphoma who have had 3 or more prior lines of therapy.
At a 2-year follow-up,...
09/29/2025
Oncology
News
Tazemetostat Demonstrates Effiacy, Safety Among Patients With EZH2-Mutant and EZH2 Wild-Type Relapsed/Refractory Follicular Lymphoma
09/29/2025
Emily Estrada
Tazemetostat demonstrates safety and efficacy for patients with EZH2-mutated or EZH2 wild-type relapsed/refractory follicular lymphoma.
Tazemetostat demonstrates safety and efficacy for patients with EZH2-mutated or EZH2 wild-type relapsed/refractory follicular lymphoma.
Tazemetostat demonstrates safety...
09/29/2025
Oncology
News
Varnimcabtagene Autoleucel Therapy Achieves Durable Remissions With Manageable Toxicity for R/R Follicular Lymphoma
09/29/2025
Emily Estrada
According to results from the CART19-BE-01 trial, varnimcabtagene autoleucel demonstrated deep and durable responses among patients with relapsed/refractory follicular lymphoma, as well as reduced financial and hospital stay burden.
According to results from the CART19-BE-01 trial, varnimcabtagene autoleucel demonstrated deep and durable responses among patients with relapsed/refractory follicular lymphoma, as well as reduced financial and hospital stay burden.
According to results from the...
09/29/2025
Oncology

News

News
Pathologic Grade and Peripheral Blood NK Cell Percentage May Predict Outcomes Among Patients With Follicular Lymphoma
12/03/2025
Emily Estrada
Pathological grade and natural killer cell levels may serve as clinically useful biomarkers for prognosis among patients with follicular lymphoma, according to a real-world study.
Pathological grade and natural killer cell levels may serve as clinically useful biomarkers for prognosis among patients with follicular lymphoma, according to a real-world study.
Pathological grade and natural...
12/03/2025
Oncology
News
Real-World Safety Analysis Identifies Undocumented Adverse Events Among Patients With Follicular Lymphoma Treated With Obinutuzumab
12/03/2025
Emily Estrada
A real-world pharmacovigilance analysis of reports from the FAERS and JADER databases identified previously undocumented adverse events linked to obinutuzumab therapy for patients wtih follicular lymphoma and chronic lymphocytic leukemia.
A real-world pharmacovigilance analysis of reports from the FAERS and JADER databases identified previously undocumented adverse events linked to obinutuzumab therapy for patients wtih follicular lymphoma and chronic lymphocytic leukemia.
A real-world pharmacovigilance...
12/03/2025
Oncology
News
CAR T-Cell Therapy Offers Superior Efficacy Over Bispecific Antibodies for R/R Follicular Lymphoma but With Higher Toxicity, Meta-Analysis Finds
11/05/2025
Emily Estrada
For patients with R/R FL, treatment with CAR T-cell therapy demonstrated superior responses compared to treatment with bispecific antibodies, despite an increased risk for neurotoxicity, according to a systematic review.
For patients with R/R FL, treatment with CAR T-cell therapy demonstrated superior responses compared to treatment with bispecific antibodies, despite an increased risk for neurotoxicity, according to a systematic review.
For patients with R/R FL,...
11/05/2025
Oncology
News
Fixed-Duration Epcoritamab Plus R2 Produces High Response Rates and Favorable Outcomes for R/R Follicular Lymphoma
11/05/2025
Emily Estrada
A regimen of fixed-duration epcoritamab with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma showed deep and durable responses, according to updated results from the EPCORE NHL-2 trial.
A regimen of fixed-duration epcoritamab with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma showed deep and durable responses, according to updated results from the EPCORE NHL-2 trial.
A regimen of fixed-duration...
11/05/2025
Oncology
News
CAR T-Cell Therapies Show Superior Survival Outcomes Compared to Real-World Salvage Treatments for R/R Follicular Lymphoma
11/05/2025
Emily Estrada
In a real-world setting, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel demonstrate superior survival outcomes compared to traditional salvage therapy for patients with follicular...
In a real-world setting, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel demonstrate superior survival outcomes compared to traditional salvage therapy for patients with follicular...
In a real-world setting, CAR...
11/05/2025
Oncology
News
Relmacabtagene Autoleucel Achieves Durable Responses With Manageable Safety For R/R FL: 2-Year Follow-Up From RELIANCE Study
09/29/2025
Emily Estrada
At a 2-year follow-up, relmacabtagene autoleucel demonstrates deep and durable responses for patients with relapsed/refractory follicular lymphoma who have had 3 or more prior lines of therapy.
At a 2-year follow-up, relmacabtagene autoleucel demonstrates deep and durable responses for patients with relapsed/refractory follicular lymphoma who have had 3 or more prior lines of therapy.
At a 2-year follow-up,...
09/29/2025
Oncology
News
Tazemetostat Demonstrates Effiacy, Safety Among Patients With EZH2-Mutant and EZH2 Wild-Type Relapsed/Refractory Follicular Lymphoma
09/29/2025
Emily Estrada
Tazemetostat demonstrates safety and efficacy for patients with EZH2-mutated or EZH2 wild-type relapsed/refractory follicular lymphoma.
Tazemetostat demonstrates safety and efficacy for patients with EZH2-mutated or EZH2 wild-type relapsed/refractory follicular lymphoma.
Tazemetostat demonstrates safety...
09/29/2025
Oncology
News
Varnimcabtagene Autoleucel Therapy Achieves Durable Remissions With Manageable Toxicity for R/R Follicular Lymphoma
09/29/2025
Emily Estrada
According to results from the CART19-BE-01 trial, varnimcabtagene autoleucel demonstrated deep and durable responses among patients with relapsed/refractory follicular lymphoma, as well as reduced financial and hospital stay burden.
According to results from the CART19-BE-01 trial, varnimcabtagene autoleucel demonstrated deep and durable responses among patients with relapsed/refractory follicular lymphoma, as well as reduced financial and hospital stay burden.
According to results from the...
09/29/2025
Oncology
FDA Approval
FDA Grants Approval to Tafasitamab for Patients With Relapsed/Refractory Follicular Lymphoma
06/18/2025
Emily Estrada
The US FDA approved tafasitamab with lenalidomide and rituximab for the treatment adults with relapsed/refractory follicular lymphoma.
The US FDA approved tafasitamab with lenalidomide and rituximab for the treatment adults with relapsed/refractory follicular lymphoma.
The US FDA approved tafasitamab...
06/18/2025
Oncology
Conference Coverage
Amulirafusp Alfa Plus Lenalidomide Shows Promising Response Rates for Relapsed/Refractory Follicular Lymphoma
06/06/2025
Emily Estrada
Amulirafusp alfa demonstrated promising response rates and a manageable safety profile for patients with relapsed/refractory CD20-positive follicular lymphoma, according to data presented at the ASCO Annual Meeting.
Amulirafusp alfa demonstrated promising response rates and a manageable safety profile for patients with relapsed/refractory CD20-positive follicular lymphoma, according to data presented at the ASCO Annual Meeting.
Amulirafusp alfa demonstrated...
06/06/2025
Oncology

Interactive Features

Quiz
CAR T-Cell Therapies and Survival Outcomes Among Patients With R/R FL
12/03/2025
True or False: According to results from a comparative analysis, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, demonstrated superior survival outcomes among patients with R/R...
True or False: According to results from a comparative analysis, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, demonstrated superior survival outcomes among patients with R/R...
True or False: According to...
12/03/2025
Oncology
Quiz
Relmacabtagene Autoleucel for R/R Follicular Lymphoma
10/30/2025
Emily Estrada
True or False: Among heavily pretreated patients with R/R follicular lymphoma, relmacabtagene autoleucel demonstrated deep and durable responses with a favorable safety profile, according to results from the phase 2 RELIANCE study.
True or False: Among heavily pretreated patients with R/R follicular lymphoma, relmacabtagene autoleucel demonstrated deep and durable responses with a favorable safety profile, according to results from the phase 2 RELIANCE study.
True or False: Among heavily...
10/30/2025
Oncology
Quiz
Amulirafusp Alfa Plus Lenalidomide for R/R FL
09/24/2025
True or False: According to a phase 2 trial, the combination of amulirafusp alfa and lenalidomide demonstrated encouraging early clinical activity and an acceptable safety profile among patients with R/R CD20-positive follicular lymphoma.
True or False: According to a phase 2 trial, the combination of amulirafusp alfa and lenalidomide demonstrated encouraging early clinical activity and an acceptable safety profile among patients with R/R CD20-positive follicular lymphoma.
True or False: According to a...
09/24/2025
Oncology
Quiz
Odronextamab Treatment for Patients With Heavily Pretreated R/R Follicular Lymphoma
10/01/2024
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to...
10/01/2024
Oncology
Quiz
Chemo-Free Mosunetuzumab Monotherapy for 3 L+ Follicular Lymphoma
03/27/2024
True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...
True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...
True or False: According to...
03/27/2024
Oncology
Quiz
Treating Follicular Lymphoma With Obinutuzumab Immunochemotherapy Versus Rituximab Immunochemotherapy
02/05/2024
What was the key finding from the phase 3 GALLIUM trial comparing the efficacy and safety of obinutuzumab-based immunochemotherapy with rituximab-based immunochemotherapy among patients with previously untreated follicular lymphoma?
What was the key finding from the phase 3 GALLIUM trial comparing the efficacy and safety of obinutuzumab-based immunochemotherapy with rituximab-based immunochemotherapy among patients with previously untreated follicular lymphoma?
What was the key finding from...
02/05/2024
Oncology
Quiz
Zanubrutinib Plus Obinutuzumab vs Obinutuzumab Alone for R/R FL
01/29/2024
True or False: Findings from the ROSEWOOD trial indicated that among patients with R/R follicular lymphoma previously treated with at least 2 lines of therapy, obinutuzumab alone demonstrated meaningful activity, manageable safety, and a...
True or False: Findings from the ROSEWOOD trial indicated that among patients with R/R follicular lymphoma previously treated with at least 2 lines of therapy, obinutuzumab alone demonstrated meaningful activity, manageable safety, and a...
True or False: Findings from the...
01/29/2024
Oncology
Quiz
Predictive Value of Ki67 Expression for Follicular Lymphoma
08/03/2023
True or False: In a study assessing potential predictive biomarkers for follicular lymphoma, results indicated that high follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma...
True or False: In a study assessing potential predictive biomarkers for follicular lymphoma, results indicated that high follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma...
True or False: In a study...
08/03/2023
Oncology
Quiz
Subcutaneous Rituximab for Low-Tumor Burden FL
06/07/2023
True or False: In a study assessing the efficacy and safety of subcutaneous rituximab following induction therapy among patients with low-tumor burden follicular lymphoma, high rituximab exposure during the start of treatment was associated...
True or False: In a study assessing the efficacy and safety of subcutaneous rituximab following induction therapy among patients with low-tumor burden follicular lymphoma, high rituximab exposure during the start of treatment was associated...
True or False: In a study...
06/07/2023
Oncology
Quiz
EZH2 Inhibitor PF-06821497 for Follicular Lymphoma
05/30/2023
True or False: In a study assessing the efficacy and safety of EZH2 inhibitor PF-06821497 among patients with follicular lymphoma, the monotherapy expansion dose was determined to be 75-625 mg twice daily.
True or False: In a study assessing the efficacy and safety of EZH2 inhibitor PF-06821497 among patients with follicular lymphoma, the monotherapy expansion dose was determined to be 75-625 mg twice daily.
True or False: In a study...
05/30/2023
Oncology

Recent News

News
Real-World Safety Analysis Identifies Undocumented Adverse Events Among Patients With Follicular Lymphoma Treated With Obinutuzumab
12/03/2025
Emily Estrada
A real-world pharmacovigilance analysis of reports from the FAERS and JADER databases identified previously undocumented adverse events linked to obinutuzumab therapy for patients wtih follicular lymphoma and chronic lymphocytic leukemia.
A real-world pharmacovigilance analysis of reports from the FAERS and JADER databases identified previously undocumented adverse events linked to obinutuzumab therapy for patients wtih follicular lymphoma and chronic lymphocytic leukemia.
A real-world pharmacovigilance...
12/03/2025
Oncology
News
CAR T-Cell Therapy Offers Superior Efficacy Over Bispecific Antibodies for R/R Follicular Lymphoma but With Higher Toxicity, Meta-Analysis Finds
11/05/2025
Emily Estrada
For patients with R/R FL, treatment with CAR T-cell therapy demonstrated superior responses compared to treatment with bispecific antibodies, despite an increased risk for neurotoxicity, according to a systematic review.
For patients with R/R FL, treatment with CAR T-cell therapy demonstrated superior responses compared to treatment with bispecific antibodies, despite an increased risk for neurotoxicity, according to a systematic review.
For patients with R/R FL,...
11/05/2025
Oncology
News
Fixed-Duration Epcoritamab Plus R2 Produces High Response Rates and Favorable Outcomes for R/R Follicular Lymphoma
11/05/2025
Emily Estrada
A regimen of fixed-duration epcoritamab with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma showed deep and durable responses, according to updated results from the EPCORE NHL-2 trial.
A regimen of fixed-duration epcoritamab with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma showed deep and durable responses, according to updated results from the EPCORE NHL-2 trial.
A regimen of fixed-duration...
11/05/2025
Oncology
News
CAR T-Cell Therapies Show Superior Survival Outcomes Compared to Real-World Salvage Treatments for R/R Follicular Lymphoma
11/05/2025
Emily Estrada
In a real-world setting, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel demonstrate superior survival outcomes compared to traditional salvage therapy for patients with follicular...
In a real-world setting, CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel demonstrate superior survival outcomes compared to traditional salvage therapy for patients with follicular...
In a real-world setting, CAR...
11/05/2025
Oncology
News
Relmacabtagene Autoleucel Achieves Durable Responses With Manageable Safety For R/R FL: 2-Year Follow-Up From RELIANCE Study
09/29/2025
Emily Estrada
At a 2-year follow-up, relmacabtagene autoleucel demonstrates deep and durable responses for patients with relapsed/refractory follicular lymphoma who have had 3 or more prior lines of therapy.
At a 2-year follow-up, relmacabtagene autoleucel demonstrates deep and durable responses for patients with relapsed/refractory follicular lymphoma who have had 3 or more prior lines of therapy.
At a 2-year follow-up,...
09/29/2025
Oncology
News
Tazemetostat Demonstrates Effiacy, Safety Among Patients With EZH2-Mutant and EZH2 Wild-Type Relapsed/Refractory Follicular Lymphoma
09/29/2025
Emily Estrada
Tazemetostat demonstrates safety and efficacy for patients with EZH2-mutated or EZH2 wild-type relapsed/refractory follicular lymphoma.
Tazemetostat demonstrates safety and efficacy for patients with EZH2-mutated or EZH2 wild-type relapsed/refractory follicular lymphoma.
Tazemetostat demonstrates safety...
09/29/2025
Oncology
News
Varnimcabtagene Autoleucel Therapy Achieves Durable Remissions With Manageable Toxicity for R/R Follicular Lymphoma
09/29/2025
Emily Estrada
According to results from the CART19-BE-01 trial, varnimcabtagene autoleucel demonstrated deep and durable responses among patients with relapsed/refractory follicular lymphoma, as well as reduced financial and hospital stay burden.
According to results from the CART19-BE-01 trial, varnimcabtagene autoleucel demonstrated deep and durable responses among patients with relapsed/refractory follicular lymphoma, as well as reduced financial and hospital stay burden.
According to results from the...
09/29/2025
Oncology
FDA Approval
FDA Grants Approval to Tafasitamab for Patients With Relapsed/Refractory Follicular Lymphoma
06/18/2025
Emily Estrada
The US FDA approved tafasitamab with lenalidomide and rituximab for the treatment adults with relapsed/refractory follicular lymphoma.
The US FDA approved tafasitamab with lenalidomide and rituximab for the treatment adults with relapsed/refractory follicular lymphoma.
The US FDA approved tafasitamab...
06/18/2025
Oncology
Conference Coverage
Amulirafusp Alfa Plus Lenalidomide Shows Promising Response Rates for Relapsed/Refractory Follicular Lymphoma
06/06/2025
Emily Estrada
Amulirafusp alfa demonstrated promising response rates and a manageable safety profile for patients with relapsed/refractory CD20-positive follicular lymphoma, according to data presented at the ASCO Annual Meeting.
Amulirafusp alfa demonstrated promising response rates and a manageable safety profile for patients with relapsed/refractory CD20-positive follicular lymphoma, according to data presented at the ASCO Annual Meeting.
Amulirafusp alfa demonstrated...
06/06/2025
Oncology
Conference Coverage
Subcutaneous Mosunetuzumab Demontrates Promising Efficacy in Previously Untreated High-Tumor Burden FL
06/04/2025
Emily Estrada
Interim results from the phase 2 MorningSun styudy show fixed-duration subcutaneous mosunetuzumab yields high response rates and manageable safety for patients with previously untreated high-tumor burden follicular lymphoma.
Interim results from the phase 2 MorningSun styudy show fixed-duration subcutaneous mosunetuzumab yields high response rates and manageable safety for patients with previously untreated high-tumor burden follicular lymphoma.
Interim results from the phase 2...
06/04/2025
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use